A Phase 3 interventional study of OPC-41061 (Tolvaptan) in Cardiac Edema, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 6 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-01-30.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate the plasma drug level, efficacy, and safety of 7-day repeated oral administration of OPC-41061 at 15 mg/day (treatment period 1) and subsequent 7-day repeated administration of OPC-41061 at 15 mg/day or 30 mg/day if diuretic effect is insufficient (treatment period 2) in congestive heart failure (CHF) patients with extracellular volume expansion despite conventional diuretic therapy.
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects receiving one of the following diuretic treatments since 3 days prior to the commencement of study drug administration without changing the dose or dosing regimen (including subjects scheduled to start treatment during the run-in observation period).
Exclusion Criteria:
Patients with any of the following complications or symptoms:
Subjects with any of the following complications or symptoms:
Subjects with any of the following disease histories:
Subjects with any of the following abnormal laboratory values:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OPC-41061 (Tolvaptan)
15-30mg/day,daily for 14days
Body Weight
The change of body weight from baseline at final observation
Time frame: Baseline, Day 14 or at the time of final drug administration
| Milestone | Stopped at End of Treatment Period 1 | Continued at 15 mg/Day | Dose Escalated to 30 mg/Day |
|---|---|---|---|
| Started | 36 | 14 | 2 |
| Completed | 24 | 12 | 2 |
| Not completed | 12 | 2 | 0 |
| Withdrew: Rsolution of congenitive symptoms | 3 | 0 | 0 |
| Withdrew: Adverse event | 6 | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 |
The change of body weight from baseline at final observation
| Kg | Stopped at End of Treatment Period 1 | Continued at 15 mg/Day | Dose Escalated to 30 mg/Day |
|---|---|---|---|
| Body Weight | -2.05 ± 1.86 | -1.31 ± 2.95 | -2.9 ± 2.69 |
Collected over 7 Days for stopped at end of treated period 1 group 14 Days for continued at 15 or 30 mg/day group. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stopped at End of Treatment Period 1 | — | 3/36 (8.3%) | 30/36 (83.3%) |
| Continued at 15 mg/Day | — | 1/13 (7.7%) | 12/13 (92.3%) |
| Dose Escalated to 30 mg/Day | — | 0/2 (0%) | 2/2 (100%) |
| Event | Stopped at End of Treatment Period 1 | Continued at 15 mg/Day | Dose Escalated to 30 mg/Day |
|---|---|---|---|
| Cardiac FailureCardiac disorders | 0/36 | 1/13 | 0/2 |
| Intracardiac ThrombusCardiac disorders | 1/36 | 0/13 | 0/2 |
| Cerebral Artery EmbolismNervous system disorders | 1/36 | 0/13 | 0/2 |
| Renal Failure ChronicRenal and urinary disorders | 1/36 | 0/13 | 0/2 |
| Event | Stopped at End of Treatment Period 1 | Continued at 15 mg/Day | Dose Escalated to 30 mg/Day |
|---|---|---|---|
| Ventricular TachycardiaCardiac disorders | 4/36 | 0/13 | 1/2 |
| Blood Alkaline Phosphatase IncreasedInvestigations | 0/36 | 0/13 | 1/2 |
| Blood Creatinine IncreasedInvestigations | 4/36 | 4/13 | 1/2 |
| Blood Urea IncreasedInvestigations | 6/36 | 4/13 | 1/2 |
| Blood Uric Acid IncreasedInvestigations | 6/36 | 4/13 | 1/2 |
| HyperlipidaemiaMetabolism and nutrition disorders | 0/36 | 0/13 | 1/2 |
| ThirstGeneral disorders | 14/36 | 6/13 | 0/2 |
| Blood Glucose IncreasedInvestigations | 4/36 | 4/13 | 0/2 |
| Blood Potassium IncreasedInvestigations | 3/36 | 3/13 | 0/2 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/36 | 3/13 | 0/2 |
1 Subject of Arm "Continued at 15 mg/day" was excluded from analysis because of GCP incompliance
| Age, Categorical(Participants) | Stopped at End of Treatment Period 1 | Continued at 15 mg/Day | Dose Escalated to 30 mg/Day | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 4 | 0 | 11 |
| >=65 years | 29 | 9 | 2 | 40 |
| Age, Continuous(years) | Stopped at End of Treatment Period 1 | Continued at 15 mg/Day | Dose Escalated to 30 mg/Day | Total |
|---|---|---|---|---|
| Mean | 71.3 ± 9.5 | 67.2 ± 12.7 | 78.5 ± 2.1 | 70.5 ± 10.4 |
| Sex: Female, Male(Participants) | Stopped at End of Treatment Period 1 | Continued at 15 mg/Day | Dose Escalated to 30 mg/Day | Total |
|---|---|---|---|---|
| Female | 11 | 2 | 1 | 14 |
| Male | 25 | 11 | 1 | 37 |
| Region of Enrollment(participants) | Stopped at End of Treatment Period 1 | Continued at 15 mg/Day | Dose Escalated to 30 mg/Day | Total |
|---|---|---|---|---|
| Japan | 36 | 13 | 2 | 51 |
The record gives a start of Oct 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Edema, Cardiac
Otsuka Pharmaceutical Co., Ltd. →